Key Events This Week
20 Jul: Stock opens strong at Rs.384.80 (+2.90%) despite flat market
21 Jul: Quarterly results reveal flat performance; stock drops 3.83%
22 Jul: Valuation shifts noted; stock plunges 12.70%
24 Jul: Minor recovery to Rs.323.05 (+1.62%) as week closes

Bajaj Healthcare Ltd is Rated Sell
2026-07-23 10:10:52Bajaj Healthcare Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 July 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Bajaj Healthcare Ltd Valuation Shifts Signal Changing Market Sentiment
2026-07-22 08:01:43Bajaj Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently seen its valuation parameters shift from very attractive to attractive, reflecting a nuanced change in price appeal. Despite a downgrade in its Mojo Grade from Hold to Sell as of 30 June 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more favourable entry point relative to its historical and peer averages. This article analyses the evolving valuation landscape of Bajaj Healthcare and its implications for investors.
Read full news articleAre Bajaj Healthcare Ltd latest results good or bad?
2026-07-21 19:15:33Bajaj Healthcare Ltd's latest financial results for the quarter ended June 2026 reflect a complex operational landscape. The company reported net sales of ₹165.63 crores, marking an 11.28% year-on-year growth, although this growth rate is lower than the previous year's figure of 12.54%. The standalone net profit for the same period was ₹13.89 crores, which shows a year-on-year increase of 15.81%, down from a more robust growth of 65.92% in the prior year. The operating profit before depreciation, interest, tax, and other income (PBDIT) stood at ₹28.75 crores, with an operating margin of 17.36%. This margin reflects a modest improvement compared to the previous quarter, indicating some progress in cost management and operational efficiency. However, the year-on-year comparison shows a decline in growth rates for both sales and profit, suggesting that while the company is recovering from prior losses, it fac...
Read full news article










